Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the initiation of an investigator-sponsored, adequate and well-controlled clinical trial evaluating safety, tolerability and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE